{"id":"W3034783173","doi":"10.1016/j.trecan.2020.05.009","title":"Clinical Development of BRAF plus MEK Inhibitor Combinations","year":2020,"lang":"en","type":"review","venue":"Trends in cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":352,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Company; Bristol-Myers Squibb Canada; Genentech; European Society for Medical Oncology; Exelixis; Prometheus; Roche; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; American Society of Clinical Oncology; AstraZeneca; Novartis; Spectrum Pharmaceuticals; Amgen; GlaxoSmithKline","keywords":"MEK inhibitor; Cancer research; Chemistry; Pharmacology; Medicine; MAPK/ERK pathway; Phosphorylation; Biochemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1354341508561493,"score_gpt":0.4400165371099267,"score_spread":0.3045823862537773,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}